Navigation Links
ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
Date:3/18/2013

SAN CLEMENTE, Calif., March 18, 2013 /PRNewswire/ -- ROX Medical announced enrollment of the first UK patients in the CONTROL-HTN international randomized controlled trial of the ROX FLOW procedure for the treatment of resistant hypertension (high blood pressure). The first patients were enrolled at Eastbourne General Hospital, East Sussex, UK by Doctors Neil Sulke and Stephan Furniss . For the two patients randomized to treatment, the ROX procedure was performed in the Cardiac Catheter Lab in under one hour: "It was a very enjoyable and straightforward procedure on a patient with very difficult to control blood pressure," commented Dr. Furniss. "The procedure was relatively painless and the patient showed significant improvement in blood pressure right after the procedure that we'll be anxious to monitor over the coming weeks and months." "We like the fact that the ROX procedure is reversible and that it can treat patients who are not candidates or don't seem to respond to renal denervation," added Dr. Sulke. "This could be a very important new device treatment option for resistant hypertension patients," said Dr. Furniss. "We are anxious to enroll additional patients into this exciting trial."

ROX Medical's FLOW procedure is a minimally invasive, catheter procedure to place a small coupler between the artery and vein in the upper leg. The procedure reduces peripheral vascular resistance and by diverting some arterial blood to the veins, adds lost compliance back into the vascular system. Uniquely, the FLOW procedure only involves vascular structures away from vital organs like the kidneys, has an immediate effect and is fully reversible. The procedure also doesn't require heavy pain medications common to renal ablation techniques. The ROX procedure holds the promise of a meaningful long-term reduction in hypertension that may be combined with other device hypertension therapies.

"We are honored and excited to have the highly respected team of cardiologists at Eastbourne involved in the CONTROL-HTN study," said ROX CEO Rodney Brenneman .

The ROX FLOW procedure for hypertension is not approved for use in the U.S.


'/>"/>
SOURCE ROX Medical
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. Medical Device Developers - Network at BIOMEDevice Boston Next Week
3. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
4. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
5. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
6. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Essential Medical Dismisses Patent Case against Masimo and Cercacor
9. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
10. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
11. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... January 17, 2017 OilPrice.com Market ... earn millions in revenue with the planned upcoming release ... of strokes with a simple test that is affordable ... latest developments in the markets today include:  Amgen Inc. ... AZN ), Cancer Genetics, Inc. (NASDAQ: ...
(Date:1/17/2017)... , Jan. 17, 2017  Maureen L. ... announces the addition of 6 senior sales leaders ... TubeClear® System.  These sales leaders were formerly part ... medical device company. Repeatedly recognized for their performance, ... customer expectations and establishing relationships with key customer ...
(Date:1/17/2017)... 17, 2017  Tetra Discovery Partners today announced ... as Vice President, Clinical Operations. He joins the ... Director, Clinical Project Management. "Richard joins Tetra ... in global clinical research planning and execution, and ... operation build-outs and development partnerships," said Mark ...
Breaking Medicine Technology:
(Date:1/17/2017)... Los Gatos, CA (PRWEB) , ... January 17, 2017 , ... ... today announced the results of a double blind clinical study for its dental gel ... to a leading national brand of toothpaste containing triclosan. The study was conducted at ...
(Date:1/17/2017)... ... 2017 , ... Many people make New Year’s resolutions or renew their commitment to better health ... easier for people who want to kick off 2017 with better smiles. Dr. Mondavi is ... These special offers include: , , A new patient package for ...
(Date:1/16/2017)... Mesa, California (PRWEB) , ... January 16, 2017 , ... ... 2014, Dr. Beazley has served on CalSouthern’s Board of Trustees and as a core ... In addition, he has been a professor of psychology at Pepperdine University, where he ...
(Date:1/16/2017)... ... January 16, 2017 , ... Houston dentist, Dr. Behzad Nazari, ... complimentary consultations and financing for orthodontics for a limited time. Complimentary for a ... about their orthodontic options. Walk-in, late-evening, Saturday, and same-day appointments are available. Antoine ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... St. Louisans are well-aware of the following ... This year’s influenza shot seems to be having no effect on keeping this ... least half of the people around are coughing, sneezing, or sniffling , ...
Breaking Medicine News(10 mins):